Compare JCSE & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JCSE | JAGX |
|---|---|---|
| Founded | 1999 | 2013 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 5.0M |
| IPO Year | 2022 | 2014 |
| Metric | JCSE | JAGX |
|---|---|---|
| Price | $0.99 | $0.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | 33.5K | ★ 444.9K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | ★ 9.10% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,689,000.00 |
| Revenue This Year | N/A | $22.41 |
| Revenue Next Year | N/A | $30.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.75 |
| 52 Week Low | $0.77 | $0.38 |
| 52 Week High | $2.50 | $15.48 |
| Indicator | JCSE | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 44.75 | 31.12 |
| Support Level | $1.00 | N/A |
| Resistance Level | $1.10 | $0.69 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 16.67 | 0.00 |
JE Cleantech Holdings Ltd is engaged in the manufacturing and selling of cleaning systems and other equipment that can be categorized into four different categories, namely aqueous washing systems, plating and cleaning systems, train cleaning systems, and other equipment, such as filtration units. The product lives of its cleaning systems and other equipment ranges from two to ten years. The company is also into designing, developing, and manufacturing other cleaning systems for various industrial end-use applications using its R&D and engineering capabilities. The company derives the majority of its revenue from the Sales of cleaning systems and other equipment. Geographically, the company derives a majority of its revenue from Singapore, followed by Malaysia.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.